Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brazil thanks early malaria diagnoses for US$3m savings

This article was originally published in Clinica

Executive Summary

Further evidence of the cost benefits of prompt management of malaria cases was cited this week by the Brazilian health ministry to highlight the importance of early diagnosis. The number of hospitalisations fell by a total of 40,000 during 2002-07, compared with levels expected from previous years, with the introduction of the national malaria programme, said the health ministry. During 1998-2001, annual hospitalisations for malaria averaged almost 19,000. By 2007, these had fallen to just over 6,300, compared with an expected 16,400. The cost savings of these reductions total almost R$6.9m (US$3m). The programme is also reducing significantly the number of infections, according to the health ministry. In Amazonia Legal state alone, 267,000 cases were reported in the first 10 months of 2008, compared with almost 400,000 during the same period the year before.

You may also be interested in...

COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers

First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts